KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) FCF Margin: 2011-2025

Historic FCF Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -32.17%.

  • Supernus Pharmaceuticals' FCF Margin fell 6252.00% to -32.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.38%, marking a year-over-year decrease of 1600.00%. This contributed to the annual value of 25.87% for FY2024, which is 768.00% up from last year.
  • Supernus Pharmaceuticals' FCF Margin amounted to -32.17% in Q3 2025, which was down 191.63% from 35.10% recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' FCF Margin peaked at 41.98% during Q2 2022, and registered a low of -32.17% during Q3 2025.
  • For the 3-year period, Supernus Pharmaceuticals' FCF Margin averaged around 17.72%, with its median value being 25.38% (2024).
  • In the last 5 years, Supernus Pharmaceuticals' FCF Margin surged by 3,517bps in 2024 and then plummeted by 6,252bps in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' FCF Margin (Quarterly) stood at 30.66% in 2021, then crashed by 1,409bps to 16.57% in 2022, then skyrocketed by 1,081bps to 27.38% in 2023, then slumped by 201bps to 25.38% in 2024, then crashed by 6,252bps to -32.17% in 2025.
  • Its FCF Margin stands at -32.17% for Q3 2025, versus 35.10% for Q2 2025 and 20.21% for Q1 2025.